Amgen at ACC.15

Amgen will present 15 abstracts including data evaluating Repatha^TM (evolocumab) and Corlanor^® (ivabradine), at the upcoming American College of Cardiology’s 64th Annual Scientific Session (ACC.15), being held March 14-16 in San Diego.

Follow Amgen on Twitter at twitter.com/amgen to receive news updates during ACC.15.

March 15, 2015	Amgen Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha™ (Evolocumab) In The New England Journal of Medicine
March 14, 2015	New Detailed Data From Phase 3 Study Show Amgen's Repatha™ (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular Risk And High Cholesterol
March 2, 2015	Amgen Showcases Cardiovascular Pipeline at ACC.15 With New Cholesterol-Lowering and Chronic Heart Failure Data

Amgen at ACC.15

Share This Story